Literature DB >> 20440852

Direct in vivo injection of 131I-GMS and its distribution and excretion in rabbit.

Yu Ma1, Yi Wan, Dong-Hui Luo, Li-Geng Duan, Lin Li, Chuan-Qin Xia, Xiao-Li Chen.   

Abstract

AIM: To explore the distribution and metabolism of (131)I-gelatin microspheres ((131)I-GMSs) in rabbits after direct injection into rabbits' livers.
METHODS: Twenty-eight healthy New Zealand rabbits were divided into seven groups, with four rabbits per group. Each rabbit's hepatic lobes were directly injected with 41.336 +/- 5.106 MBq (131)I-GMSs. Each day after (131)I-GMSs administration, 4 rabbits were randomly selected, and 250 microL of serum was collected for gamma count. Hepatic and thyroid functions were tested on days 1, 4, 8, 16, 24, 32, 48 and 64 after (131)I-GMSs administration. Single-photon emission computed tomography (SPECT) was taken for each group on days 0, 1, 4, 8, 16, 24, 32, 48, 64 after (131)I-GMSs administration. A group of rabbits were sacrificed respectively on days 1, 4, 16, 24, 32, 48, 64 after (131)I-GMSs administration. Their livers were taken out for histological examination.
RESULTS: After (131)I-GMSs administration, the nuclide was collected in the hepatic area with microspheres. The radiation could be detected on day 48 after (131)I-GMSs administration, and radiography could be seen in thyroid areas in SPECT on days 4, 8, 16 and 24. One day after (131)I-GMSs administration, the liver function was damaged but recovered 4 d later. Eight days after (131)I-GMSs administration, the levels of free triiodothyronine and free thyroxin were reduced, which restored to normal levels on day 16. Histological examination showed that the microspheres were degraded to different degrees at 24, 32 and 48 d after (131)I-GMSs administration. The surrounding parts of injection points were in fibrous sheathing. No microspheres were detected in histological examination on day 64 after (131)I-GMSs administration.
CONCLUSION: Direct in vivo injection of (131)I-GMSs is safe in rabbits. It may be a promising method for treatment of malignant tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440852      PMCID: PMC2864837          DOI: 10.3748/wjg.v16.i17.2120

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  47 in total

Review 1.  Radiation therapy in pancreatic cancer: current practice and future trends.

Authors:  W R Bodner; B S Hilaris; D A Mastoras
Journal:  J Clin Gastroenterol       Date:  2000-04       Impact factor: 3.062

2.  A comparison of the sources of cancer mortality in China.

Authors:  Ling Yang; D Maxwell Parkin; Liandi Li; Yude Chen
Journal:  Cancer Causes Control       Date:  2004-09       Impact factor: 2.506

3.  (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome.

Authors:  A A Pathirana; S Vinjamuri; C Byrne; P Ghaneh; J Vora; G J Poston
Journal:  Eur J Surg Oncol       Date:  2001-06       Impact factor: 4.424

Review 4.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  Time trends in cancer mortality in China: 1987-1999.

Authors:  Ling Yang; Donald M Parkin; Liandi Li; Yude Chen
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

6.  Thyroid uptake of liquid versus capsule 131I tracers in hyperthyroid patients treated with liquid 131I.

Authors:  J N Rini; S Vallabhajosula; P Zanzonico; J R Hurley; D V Becker; S J Goldsmith
Journal:  Thyroid       Date:  1999-04       Impact factor: 6.568

Review 7.  Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.

Authors:  Riad Salem; Kenneth G Thurston; Brian I Carr; James E Goin; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2002-09       Impact factor: 3.464

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.

Authors:  K K Matthay; J P Huberty; R S Hattner; A R Ablin; B L Engelstad; S Zoger; B H Hasegawa; D Price
Journal:  J Nucl Biol Med       Date:  1991 Oct-Dec

10.  Anticancer gelatin microspheres with multiple functions.

Authors:  C H Yan; X W Li; X L Chen; D Q Wang; D C Zhong; T Z Tan; H Kitano
Journal:  Biomaterials       Date:  1991-09       Impact factor: 12.479

View more
  2 in total

1.  131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment.

Authors:  Yu Ma; Ligeng Duan; Lin Li; Wusheng Lu; Bo Li; Xiaoli Chen
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (¹³¹I-GMSs) following intratumoral injection.

Authors:  Chuan-Chao Li; Jun-Lin Chi; Yu Ma; Jian-Hong Li; Chuan-Qin Xia; Lin Li; Zhuo Chen; Xiao-Li Chen
Journal:  Radiat Oncol       Date:  2014-06-23       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.